All Cases

Pre-commercialization and Launch Strategy

Identified Drivers of Physician Switch in dry eye disease, informing the commercial strategy of a mid-sized, ophthalmology company 

Mapped treatment landscape for a rare ophthalmology indication in APAC for a mid-sized pharmaceutical company, including eligible patient population and pricing levels

Developed a lifecycle-revenue-maximizing pricing strategy for a large pharma CNS treatment

Evaluated emerging markets for a large pharma client to understand specific health system support strategies required to successfully manage a new multiple sclerosis treatment

Assessed the Mexican private payer migraine market to understand the current market situation, synthesize the commercial opportunity and develop a launch strategy for migraine products

Defined and compared the treatment paradigms for two types of depression in several LATAM markets with the global “gold standard” to understand the value of programs designed to improve patient care

Assessed UK treatment constraints and system-wide capacity for a multiple sclerosis therapy, ultimately optimizing and informing the strategic action plan of a large pharmaceutical company

Identified expected penetration and uptake of a DMD therapy in EU-4 + UK using LSC center-based assessment (CBA) methodology to inform 5-year commercial forecast and dependent business decisions at a mid-sized European pharmaceutical company  

Developed global view of heath systems’ capacity to administer a novel Alzheimer’s drug to inform investment decisions at a large pharmaceutical company

Assessed landscape and physician segmentation evolution in multiple sclerosis to inform strategic commercial decisions at a small biotech